JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M403891200 on July 6, 2004

J. Biol. Chem., Vol. 279, Issue 38, 39317-39330, September 17, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/38/39317    most recent
M403891200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Sidhu, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.
Right arrow Articles by Sidhu, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

D1 Dopamine Receptor Mediates Dopamine-induced Cytotoxicity via the ERK Signal Cascade*

Jun Chen{ddagger}, Milan Rusnak{ddagger}, Robert R. Luedtke§, and Anita Sidhu{ddagger}

From the {ddagger}Department of Pediatrics, Georgetown University, Washington, D. C. 20007 and the §Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107

Received for publication, April 7, 2004 , and in revised form, May 21, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Postsynaptic striatal neurodegeneration occurs through unknown mechanisms, but it is linked to high extracellular levels of synaptic dopamine. Dopamine-mediated cytotoxicity of striatal neurons occurs through two distinct pathways: autoxidation and the D1 dopamine receptor-linked signaling pathway. Here we investigated the mitogen-activated protein kinase (MAPK) signaling pathways activated upon the acute stimulation of D1 dopamine receptors. In SK-N-MC neuroblastoma cells, endogenously expressing D1 dopamine receptors, dopamine caused activation of phosphorylated (p-)ERK1/2 and of the stress-signaling kinases, p-JNK and p-p38 MAPK, in a time- and dose-dependent manner. Selective stimulation of D1 receptors with the agonist SKF R-38393 caused p-ERK1/2, but not p-JNK or p-p38 MAPK activation, in a manner sensitive to the receptor-selective antagonist SCH 23390, protein kinase A inhibition (KT5720), and MEK1/2 inhibition (U0126 or PD98059). Activation of ERK by D1 dopamine receptors resulted in oxidative stress and cytotoxicity. In cells transfected with a catalytically defective mutant of MEK1, the upstream ERK-specific kinase, both dopamine- and SKF R-38393-mediated cytotoxicity was markedly attenuated, confirming the participation of the ERK signaling pathway. Cell fractionation studies showed that only a small amount of p-ERK1/2 was translocated to the nucleus, with the majority retained in the cytoplasm. From coimmunoprecipitation studies, p-ERK was found to form stable heterotrimeric complexes with the D1 dopamine receptor and {beta}-arrestin2. In cells transfected with the dominant negative mutant of {beta}-arrestin2, the formation of such complexes was substantially inhibited. These data provide novel mechanistic insights into the role of ERK in the cytotoxicity mediated upon activation of the D1 dopamine receptor.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Striatal neurodegeneration is found in several human disorders involving postsynaptic dopamine neuronal dysfunction, such as the L-dopa-unresponsive parkinsonism subtype of multiple system atrophy (1), methamphetamine-induced neurotoxicity (2, 3), and secondary dopamine dysfunction in Huntington's disease (4), in which dopaminergic transmission is interrupted by progressive loss of the striatal neurons bearing the postsynaptic D1 and D2 dopamine receptors (5). Although all of these diseases are characterized by elevated dopamine levels in the synapse, the underlying pathological mechanism(s) promoting striatal degeneration remains enigmatic. Recent studies suggest a role for the participation of both reactive oxygen species and reactive nitrogen species in the degeneration of striatal neurons (6–9). Reactive oxygen species and reactive nitrogen species may be produced through autoxidation of extracellular dopamine in the synapse and may be especially important in the striatal degeneration seen in the L-dopa-unresponsive parkinsonism subtype of multiple system atrophy (1, 10).

Dopamine in the synapse causes activation of the postsynaptic D1 and D2 subtypes of the dopamine receptor. Accumulating evidence in primates indicates that blockage of D1 dopamine receptors with selective antagonists has strong neuroprotective and anti-parkinsonian effects (11, 12), supporting a coparticipatory role of the D1 receptors in the maintenance and/or pathogenesis of postsynaptic neurodegeneration. In both rat striatal primary cultures (13) and in SK-N-MC neuroblastoma cells (14), which endogenously express a functional D1 dopamine receptor (15), we have shown recently that the chronic treatment of these cells with dopamine promotes increased expression of the nitric-oxide synthases, neuronal nitric-oxide synthase and inducible nitric-oxide synthase, accompanied by increased nitric oxide production, oxidative stress, and cytotoxicity. These effects of dopamine were only partially mimicked by the oxidant H2O2 and by direct stimulation of the D1 dopamine receptor with the selective agonist SKF R-38393. Dopamine effects were only partly blocked by the antioxidant sodium metabisulfite (SMBS)1 and by the D1 receptor antagonist SCH 23390. However, together these compounds completely ablated the actions of dopamine (13, 14). These data suggest that dopamine-mediated responses are mediated by at least two distinct and nonoverlapping pathways: through extracellular autoxidation of the compound and through chronic activation of the D1 dopamine receptor.

The current studies were undertaken to examine further the procytotoxic signaling pathways activated by D1 dopamine receptors. We examined the role of mitogen-activated protein kinases (MAPKs), the downstream mediators of signal transduction from the cell surface receptors to the nucleus. MAPKs have been implicated in a wide variety of cellular processes such as proliferation, differentiation, and apoptotic cell death. In mammals, three major groups of MAPKs have been identified: extracellular signal-regulated kinases 1 and 2 (ERK1/2) (16), p38 MAPK (17), and c-Jun N-terminal kinase (JNK) (18). The ERK-linked signaling pathways are stimulated by receptor tyrosine kinases (19) and G protein-coupled receptors (GPCRs) (20) and generally lead to a mitogenic and proliferative response (21). JNK and p38 MAPK are stimulated by cellular stresses, such as free radicals and inflammatory agents, leading to apoptotic cell death (22). In the present studies, the activation of MAPKs was assessed by examining the expression levels and function of the phosphorylated MAPKs: p-JNK, p-p38 MAPK, and p-ERK1/2. Instead of observing an elevation of the archetypical proapoptosis MAPKs, p-JNK and p-p38 MAPK, we surprisingly found that D1 dopamine receptors selectively stimulated the ERK1/2 signaling cascade. Moreover, the activated p-ERK1/2 was primarily retained in the cytoplasm and formed a heterotrimeric complex with the D1 receptor and {beta}-arrestin2, with only low levels seen in the nuclei, suggesting that the failure of p-ERK to be translocated into the nucleus may be linked to the subsequent cytotoxic response. Our findings underscore a novel and selective mechanism by which stimulation of D1 dopamine receptors promotes oxidative stress and cytotoxicity while providing a heuristic view in which to evaluate alternate roles of p-ERK1/2 in mediating these cellular responses.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Human SK-N-MC neuroblastoma cells were obtained from the American Type Culture Collection (Rockville, MD). Dopamine, hydrogen peroxide (H2O2), SMBS, SKF R-38393, SCH 23390, and forskolin were purchased from Sigma. KT5720, U0126, SB203580, and PD98059 were from Calbiochem, and SB600125 was from Biomol%20Research%20Laboratories">Biomol Research Laboratories, Inc.

Cell Culture, Drug Treatment, and Cell Viability—Human neuroblastoma-derived SK-N-MC cells were grown in 12-well culture plates (seeding density, 1.0 x 105/well) in RPMI 1640 medium without phenol red, supplemented with 10% (v/v) Nu-serum (Collaborative Biomedical Products, Bedford, MA), antibiotics, and 2 mM L-glutamine in a humidified atmosphere of 95% air, 5% CO2 at 37 °C until 90% confluent. Cells were then serum starved overnight with serum-free RPMI medium and incubated with various drugs for 16 h or the indicated times. Control cells were treated with an equal concentration of solvent (0.2% H2O). After incubation, 0.3 ml of medium was removed to measure nitrite concentration. Cell viability in 12-well plates was evaluated by counting viable cells in a Neubauer cell using the trypan blue exclusion test, as described by the manufacturer's (Sigma) protocol, whereby viable cells exposed to trypan blue for no more than 15 min exclude the dye. Values from each treatment were expressed as a percentage of cell survival relative to control.

Plasmids and Transfection—Wild type MEK1 and catalytically defective MEK1 mutant (MEK1-K97M) cDNA were kind gifts from M. Cobb, University of Texas Southwestern Medical Center, Dallas, TX. The MEK1-K97M cDNA construct was subcloned into vector pRSET (Invitrogen), and the wild type MEK1 cDNA construct was subcloned into vector pCMV5 (Invitrogen). {beta}-Arrestin1 dominant negative mutant ({beta}-arrestin1 V53D) and {beta}-arrestin2 dominant negative mutant ({beta}-arrestin2 V54D) cDNA constructs (gifts from M. G. Caron, Duke University, Durham, NC) were subcloned into the mammalian expression vector pcDNA1AMP (Invitrogen). SK-N-MC neuroblastoma cells were transiently transfected (1 µg of DNA/105 cells) by LipofectAMINE 2000 (Invitrogen). Briefly, cells were seeded in 12 wells (105 cells seeded/well) and grown to 80% confluence on the day of transfection. DNA-LipofectAMINE 2000 was prepared as follows. Diluted DNA in Opti-MEM (without serum) was brought to a concentration of 1.6 µg/100 µl. Then diluted LipofectAMINE 2000 reagent in Opti-MEM (without serum) was brought to a concentration of 4.0 µl/100 µl, mixed gently, and incubated for 5 min at room temperature. After a 5-min incubation, the diluted DNA was combined with the diluted LipofectAMINE 2000, mixed gently, and incubated for 20 min at room temperature to allow DNA-LipofectAMINE 2000 complexes to form. 200 µl of the DNA-LipofectAMINE 2000 complex was added to each well containing cells and Dulbecco's modified Eagle's medium (without serum and antibiotics), mixed gently, and incubated at 37 °C and 5% CO2 for 5 h. After the 5-h incubation, the medium was replaced with Dulbecco's modified Eagle's medium containing 20% fetal bovine serum and used 48 h after transfection. Mock transfected cells were transfected with a pcDNA3 plasmid (Invitrogen) that lacked a DNA insert.

Measurement of Nitrite Concentration—The nitrite concentration was measured as described previously (13, 14). Briefly, 0.3 ml of Griess reagent (1 part of 0.1% naphthylethylenediamine dihydrochloride in H2O and 1 part of 1% sulfanilamide in 5% H3PO4) and 0.3 ml of culture medium from treated cells (see above) were mixed. After a 30-min incubation at 45 °C, the absorbance was determined at 550 nm. The nitrite concentration was measured from a standard curve using NaNO2 at a range of 0–10 µM. Results were expressed as nM/1.0 x 105 cells or -fold increase of the nitrite level from drug treatment over a distilled water-treated control.

Protein Preparation and Immunoblot Analysis—SK-N-MC cells were lysed in buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM {beta}-glycerolphosphate, 1 mM Na3VO4) containing 5 µg/ml leupeptin, 5 µg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. Protein concentrations were determined by the Bradford method (23). Immunoblot analysis was performed essentially as described previously (24). Briefly, protein (50 µg/lane) was separated eletrophoretically using 10% SDS-PAGE and transferred overnight to polyvinylidene difluoride membranes (Micron Separations Inc., Westboro, MA). The membranes were blocked with 5% nonfat dried milk in Tris-buffered saline with Tween 20 (TBST; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween 20) followed by incubation in primary antibodies. The blots were then washed and incubated with secondary antibody. Enhanced chemiluminescence was carried out using Renaissance Chemiluminescence Reagent Plus (PerkinElmer Life Sciences). The primary antibodies used were as follows: p-ERK1/2, p-JNK and p-p38 MAPK mouse monoclonal antibody (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA), p-MEK1/2 rabbit polyclonal antibody (1:1,000, Cell Signaling Technology, Beverly, MA). The optical density of the immunoblots was quantified by NIH Image.

Coimmunoprecipitation Studies—Untransfected or transfected SK-N-MC cells (1–2 x 107 cells) were solubilized with 1% sodium cholate (Sigma) as described previously (25). To the soluble extracts (200–400 µl/assay tube, 1–1.5 mg/ml of protein), either of the following antisera was added (1:100): p-ERK1/2 rabbit monoclonal (Cell Signaling Technology, Inc., Beverly, MA) or pan-{beta}-arrestin rabbit polyclonal (Affinity BioReagents, Golgen, CO) or mouse anti-D1 monoclonal (26). After overnight incubation, immune complexes were precipitated with protein A-Sepharose beads (CL-4B, Amersham Biosciences). Pellets were washed five times and subjected to SDS-PAGE and Western blotting. Blots were probed with antibodies (1:1,000) for either p-ERK1/2 mouse monoclonal (Santa Cruz Biotechnology) or {beta}-arrestin2 mouse monoclonal (Santa Cruz Biotechnology) or D1 dopamine receptors mouse monoclonal (26). Proteins were visualized using peroxidase-conjugated secondary antibodies (1:8,000; Santa Cruz Biotechnology) and enhanced chemiluminescence (Amersham Biosciences). p-ERK1/2 was detected as two bands, about 42 and 44 kDa; {beta}-arrestin2 had a band of about 47 kDa, and D1 is about 50 kDa, consistent with the known molecular sizes reported in the literature.

Subcellular Fractionation—For the separation of nuclear and cytosolic pools of endogenous p-ERK1/2, serum-starved cells were stimulated with dopamine or SKF R-38393. Monolayers were washed twice with ice-cold phosphate-buffered saline and solubilized with 2 ml of ice-cold lysis buffer. Cells were incubated on ice for 10 min to allow lysis. The cellular extract was centrifuged at 500 x g for 5 min to pellet nuclei. The supernatants contained the cytosolic fraction. Pellets containing cell nuclei were washed with lysis buffer and pelleted again at 500 x g for 10 min. Both cytosolic and nuclear fractions were solubilized in 2 x Laemmli loading buffer, and p-ERK1/2 levels were determined by immunoblotting. The purity of nuclear and cytosolic fractions was verified by immunoblotting with antibodies to Elk-1.

Analysis of Data—All statistical analyses values were accomplished using Instat Statistical Software (GraphPad, Sorrento Valley, CA). Statistical comparisons were performed with one-factor analysis of variance followed by Fisher's least squares difference test. Values of p < 0.05 were considered statistically significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Activation of D1 Dopamine Receptors Enhances Oxidative Stress and Cytotoxicity—We have shown previously that chronic (16 h) stimulation of D1 dopamine receptors with dopamine or D1 receptor selective agonist, SKF R-38393, causes profound cytotoxicity, as indexed by increased oxidative stress and accelerated cell death (14). SK-N-MC neuroblastoma cells, a postsynaptic striatal cell model endogenously expressing the D1 receptors (15, 27), were treated with increasing concentrations of dopamine in the presence of SCH 23390, a D1-selective antagonist, or SMBS, a potent antioxidant. In the presence of either of these two compounds, the cytotoxic effects of dopamine were reduced sharply by ~50%, as indexed by a decrease in both nitrite production (Fig. 1A) and cell death (Fig. 1B). When SCH 23390 and SMBS were used together, the cytotoxic effects of dopamine were completely prevented, indicating that both autoxidation of dopamine and direct activation of the D1 receptors by dopamine contribute to mediation of dopamine cytotoxicity.



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 1.
Dopamine (DA) effects on oxidative stress and cytotoxicity are partially mediated by the activation of D1 dopamine receptors. The nitrite production (A) and cytotoxicity (B) induced by dopamine with the indicated doses (0–200 µM) was partially blocked by a cotreatment with the D1 receptor-selective antagonist SCH 23390 or the antioxidant SMBS and almost completely blocked by a cotreatment with both SCH 23390 and SMBS. 10 µM SCH 23390 and 200 µM SMBS were added 15 min before dopamine treatment. The nitrite generation (C) and cytotoxic effect (D) of SKF R-38393 were blocked by the D1 receptor-selective antagonist SCH 23390 but not by the antioxidant SMBS. 10 µM SCH 23390 and 200 µM SMBS were applied 15 min before the indicated doses of SKF R-38393. The values shown are the average ± S.E. of three experiments conducted in duplicate.

 
The direct participation of D1 dopamine receptors in inducing cytotoxicity was tested by stimulating the receptor with the D1-selective agonist SKF R-38393 in the absence or presence of SMBS or SCH 23390. Treatment of SK-N-MC cells with SKF R-38393 caused an increase in both nitrite levels (Fig. 1C) and cell death (Fig. 1D). SMBS did not modulate the SKF R-38393-mediated effects, consistent with lack of oxidation of this stable compound. By contrast, SCH 23390 attenuated the effects of SKF R-38393 with regard to both nitrite production and cell death.

Dopamine Enhances Phosphorylation of the ERK1/2 MAP Kinases—To gain insight into the mechanistic pathways by which dopamine mediates its toxic effects, we analyzed the early signaling cascades that are activated by examining the phosphorylation of the three major groups of MAP kinases: ERK1/2, JNK, and p38 MAPK, in SK-N-MC cells treated with dopamine or H2O2. Dopamine caused a strong enhancement of p-ERK1/2 in SK-N-MC cells in a dose-dependent manner, and an increase of 116 ± 14.9% was observed at the highest concentration of dopamine (100 µM) used in these studies (Fig. 2A). By contrast, H2O2 enhancement of p-ERK1/2 was weak, and even at 100 µM, a modest increase of only 33% was seen. On the other hand, dopamine caused only a weak enhancement (33%) of p-JNK, whereas H2O2 increased p-JNK levels by 65% (Fig. 2B). Dopamine and H2O2 activated p-p38 MAPK to similar levels, and increases of 143 and 133%, respectively, were observed at concentrations of 100 µM (Fig. 2C).



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 2.
Expression of phosphorylated MAP kinases in dopamine (DA)- and H2O2 immunoblot-treated SK-N-MC cells. A, analysis of p-ERK1/2 expression in SK-N-MC cells after 1 h of dopamine or H2O2 treatment for the indicated doses (0, 10, 50, 100 µM). B, immunoblot analysis of p-JNK expression in SK-N-MC cells after 1 h dopamine or H2O2 treatment. C, immunoblot analysis of p-p38 MAPK expression in SK-N-MC cells after 1 h dopamine or H2O2 treatment. The values are expressed as the average ± S.E. of three experiments. In A–C, p < 0.05 (*) and p < 0.01 (**), significantly different from the corresponding dopamine treatment group. D, time course of p-ERK1/2, p-JNK, and p-p38 MAPK expression induced by 100 µM dopamine in SK-N-MC cells. Data are the mean ± S.E. of four independent experiments for each treatment.

 
The time course of activation of p-ERK1/2, p-JNK, and p-p38 MAPK by 100 µM dopamine was investigated. Maximal activation of p-ERK1/2 and p-p38 MAPK was achieved within 45 min of exposure to dopamine (Fig. 2D), with a slight decrease after 60 and 120 min of exposure. The weak activation of p-JNK by dopamine was seen only after 60 min and was sustained up to 120 min of exposure to dopamine. These data indicate that dopamine strongly enhances the phosphorylation of the ERK1/2 and p38 MAPKs, with weak activation of JNK.

D1 Dopamine Receptor-mediated Cytotoxicity Proceeds through the p-ERK1/2 Signaling Pathway—Because the ability of dopamine to enhance phosphorylation of ERK1/2 was much higher than that of H2O2, we speculated that the increase in p-ERK1/2 levels was not the result of the oxidant properties of these compounds, but was a direct consequence of D1 dopamine receptor stimulation by dopamine. To test for this, we examined p-ERK1/2, p-JNK, and p-p38 MAPK levels after stimulating SK-N-MC cells with the D1 receptor-selective agonist, SKF R-38393. Treatment of cells with increasing doses of SKF R-38393 selectively enhanced p-ERK1/2 levels (Fig. 3A), with no corresponding increase in either p-JNK or p-p38 MAPK levels (Fig. 3B). Moreover, the increase in p-ERK1/2 was blocked by the D1-selective antagonist SCH 23390, protein kinase A inhibitor KT5720, and by U0126, a selective inhibitor of MEK1/2 (Fig. 3A).



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 3.
Activation of D1 dopamine receptors stimulates the ERK pathway. A, SKF R-38393 induced an increased expression of p-ERK1/2 in SK-N-MC cells, which was blocked by D1 receptor-selective antagonist SCH 23390, selective protein kinase A inhibitor KT5720, and selective MEK1/2 inhibitor U0126. 10 µM SCH 23390, 5 µM KT5720, or 10 µM U0126 was applied 15 min before SKF R-38393 treatment. Cells were incubated with the indicated input doses of SKF R-38393 for 1 h. B, the expressions of p-JNK and p-p38 MAPK were not changed significantly by stimulation D1 dopamine receptors in SK-N-MC cells. C, the expression of p-MEK1/2 was enhanced by treatment with an increased dose of SKF R-38393, which was blocked by D1 receptor-selective antagonist SCH 23390. 10 µM SCH 23390 was added 15 min before the SKF R-38393 treatment. Cells were incubated with SKF R-38393 for 1 h. In the bar graph, data are the mean ± S.E. of three independent experiments for each treatment. p < 0.05 (*), significantly different from the corresponding SKF R-38393 treatment group.

 
One feature of the ERK signaling cascade is that ERK1/2 phosphorylation is exclusively regulated by MEK1/2, the upstream dual specificity kinase. This dual phosphorylation is necessary and sufficient for ERK activation. We therefore also measured p-MEK1/2 levels by stimulating SK-N-MC cells with SKF R-38393 and found a dose-dependent increase in p-MEK1/2 which was blocked completely by SCH 23390 (Fig. 3C).

To assess further the participation p-ERK1/2 in mediating dopamine and D1 receptor cytotoxicity, SK-N-MC cells were treated for 16 h with dopamine or SKF R-38393 (50 µM each) in the presence or absence of selective inhibitors of the various MAPKs, and nitrite levels and cell viability were measured. Cells were also treated with 50 µM H2O2 to measure separately the role of MAPKs in the oxidative pathway. 10 µM SB203580, a selective inhibitors of p38 MAPK, reduced nitrite production by both dopamine (47%) and H2O2 (62%), with a significant (p < 0.05) increase in cell viability (Fig. 4A). When cells were treated with SKF R-38393, SB203580 caused a modest decrease (21%) in nitrite production, without any significant changes in cell viability (Fig. 4A). By contrast, inhibition of p-JNK activity with its selective inhibitor SB600125 had virtually no significant effect on SKF R-38393-mediated nitrite production or cell death, while significantly reducing nitrite levels produced by dopamine and H2O2 (29 and 44%, respectively) (Fig. 4B).



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 4.
Effect of MAPK inhibitors on nitrite production and cell viability induced by dopamine (DA), H2O2, or SKF treatment of SK-N-MC neuroblastoma cells. A, the nitrite production and cytotoxicity induced by dopamine and H2O2 with 50 µM doses were partially blocked by a cotreatment with a selective p38 MAPK inhibitor SB203580. The nitrite production and cytotoxicity induced by 50 µM SKF R-38393 were not influenced by cotreatment with SB203580. B, the nitrite production and cytotoxicity induced by 50 µM dopamine and H2O2 were ablated by cotreatment with a selective JNK MAPK inhibitor SB600125. The nitrite production and cytotoxicity induced by 50 µM SKF R-38393 were not affected by cotreatment with SB600125. The nitrite production and cytotoxicity induced by 50 µM dopamine and SKF R-38393 were ablated by a cotreatment with selective MEK1/2 inhibitors PD98059 (C) and U0126 (D). However, the nitrite production and cytotoxicity induced by 50 µM H2O2 were not influenced by cotreatment with PD98059 (C) and U0126 (D). Kinase inhibitors (10 µM SB203580, 10 µM SB600125, 10 µM PD98059, and 10 µM U0126) were added 15 min before 50 µM dopamine, H2O2, or SKF R-38393 treatment. Values shown are the average ± S.E. of three experiments conducted in duplicate. p < 0.05 (*), significantly different from the corresponding dopamine, H2O2, or SKF R-38393 treatment group.

 
U0126 and PD98059, another selective inhibitor of MEK1/2 (10 µM each), blocked (41 and 48%, respectively) dopamine-mediated nitrite production, causing a significant (p < 0.05) increase in cell viability (Fig. 4, C and D). Moreover, both U0126 and PD98059 almost completely blocked an SKF R-38393-mediated increase in nitrite production (by 86 and 84%, respectively), while significantly (p < 0.05) restoring cell viability to near control levels (Fig. 4, C and D). By contrast, H2O2-induced nitrite production was much less affected by the presence of the MEK1/2 inhibitors, with inhibition of only 15–22% with U0126 and PD98059, respectively, and without significant changes in cell viability (Fig. 4, C and D). Together, these data suggest that the cytotoxicity observed is the result of the direct stimulation of D1 receptors and is dependent on activation of p-ERK1/2, but not p-JNK, with only a modest involvement of p-p38 MAPK in these events.

D1 Dopamine Receptor-mediated Cytotoxicity Involves MEK1—To confirm the involvement of MEK1 in D1 dopamine receptor-mediated oxidative stress and cytotoxicity, we transfected SK-N-MC cells with wild type MEK1 and its catalytically defective MEK1 mutant, MEK1-K97M. Compared with wild type MEK1-transfected SK-N-MC cells, MEK1-K97M-transfected cells had decreased nitrite production and cell death upon treatment with both dopamine and SKF R-38393 (Fig. 5A) (38 and 56%, respectively; p < 0.05), without affecting H2O2-induced nitrite production and cytotoxicity (Fig. 5A). To ascertain whether MEK1 was involved in the direct receptor stimulation pathway of dopamine action or through production of free radicals, MEK1-K97M-transfected cells were treated with dopamine (Fig. 5B), SKF R-38393 (Fig. 5C), and H2O2 (Fig. 5D) in the absence or presence of SMBS and SCH 23390. In wild type MEK1-transfected cells, dopamine-induced nitrite production and cytotoxicity were significantly (p < 0.05) and equally ablated by both SMBS and SCH 23390 (Fig. 5B). However, in MEK1-K97M-transfected cells, dopamine-induced nitrite production and cytotoxicity were only blocked upon co-treatment with the antioxidant SMBS, but not by the D1 receptor-selective antagonist SCH 23390 (Fig. 5B). Meanwhile, in wild type MEK1-transfected cells, 50 µM SKF R-38393 caused a significant (p < 0.05) increase in nitrite production and cytotoxicity, which were blocked by the D1 receptor-selective antagonist SCH 23390, but not by SMBS (Fig. 5C). In contrast to MEK1-transfected cells, SKF R-38393 had no significant effect on either nitrite production or cytotoxicity in MEK1-K97M-transfected SK-N-MC cells (Fig. 5C). On the other hand, in both wild type MEK1- and MEK1-K97M-transfected SK-N-MC cells, H2O2-induced nitrite production and cytotoxicity were only blocked by cotreatment with the antioxidant SMBS (Fig. 5D), but not by the D1 receptor-selective antagonist SCH 23390 (Fig. 5D). These results are consistent with our finding that MEK1/2 is selectively activated by D1 dopamine receptors but not through the oxidative stress pathway of dopamine autoxidation.




View larger version (83K):
[in this window]
[in a new window]
  		FIG. 5.
MEK1/ERK pathway mediates D1 dopamine (DA) receptor-induced oxidative stress and cytotoxicity. A, compared with wild type MEK1-transfected SK-N-MC cells, MEK1 mutant-transfected SK-N-MC cells ablated dopamine-induced nitrite production and cytotoxicity and blocked the nitrite production and cytotoxicity induced by SKF R-38393 compared with wild type MEK1, but had no effect on H2O2-induced nitrite production and cytotoxicity. B, in MEK1 mutant-transfected SK-N-MC cells, dopamine-induced nitrite production and cytotoxicity were blocked by cotreatment with the antioxidant SMBS, but not by the D1 receptor-selective antagonist SCH 23390. C, in MEK1 mutant-transfected SK-N-MC cells, SKF R-38393 produced no significant change in nitrite production and cytotoxicity. D, in MEK1 mutant-transfected SK-N-MC cells, H2O2-induced nitrite production and cytotoxicity were blocked by cotreatment with the antioxidant SMBS, but not by the D1 receptor-selective antagonist SCH 23390. In the A–D bar graphs, the values shown are the average ± S.E. of three experiments conducted in triplicate. p < 0.05 (*), significantly different from the corresponding dopamine, H2O2, or SKF R-38393 treatment group. E, compared with wild type MEK1-transfected SK-N-MC cells, MEK1 mutant-transfected cells ablated dopamine-induced p-ERK1/2 expression, but the MEK1/2 expression showed no significant change between wild type MEK1- and MEK1 mutant-transfected cells. F, compared with wild type MEK1-transfected SK-N-MC cells, MEK1 mutant-transfected cells ablated SKF R-38393-induced p-ERK1/2 expression, but the MEK1/2 expression had no significant change between wild type MEK1- and MEK1 mutant-transfected cells. In the E and F bar graphs, the values shown are the average ± S.E. of three experiments conducted in triplicate. p < 0.05 (*), significantly different from the corresponding wild type MEK1-transfected cells group.

 
We examined the p-ERK1/2 expression levels after transfecting cells with wild type MEK1 and the MEK1 mutant. In wild type MEK1-transfected SK-N-MC cells, dopamine and SKF R-38393 caused a strong enhancement of p-ERK1/2 in a dose-dependent manner. Maximal increases of 172.7 ± 17.6% and 94.7 ± 13.5% were observed at the highest concentration of dopamine (100 µM) and SKF R-38393 (100 µM), respectively, used in these studies (Fig. 5, E and F). However, in MEK1-K97M-transfected cells, dopamine- and SKF R-38393-induced p-ERK1/2 expressions were significantly (p < 0.05) reduced by about 45 and 73% at the highest concentration of dopamine (100 µM) and SKF R-38393 (100 µM), respectively (Fig. 5, E and F). In addition, total MEK1/2 expression was detected with no substantial difference in wild type MEK1- and MEK1-K97M-transfected cells, indicating that the reduction in p-ERK1/2 levels was not caused by changes in MEK1/2 protein levels (Fig. 5, E and F). These data clearly indicate the participation of MEK1/2 and thereby the p-ERK1/2 pathway upon activation of the D1 dopamine receptor.

p-ERK Is Retained in the Cytoplasm in a Heterotrimeric Complex—p-ERK elicits a wide range of biological functions through phosphorylation of nuclear and cytoplasmic substrates (28), and the translocation of ERK from the cytoplasm to the nucleus is mandatory for efficient regulation of cell survival and proliferation (29, 30). Because our results showed paradoxically that p-ERK promoted a cytotoxic response, we conducted studies to determine whether p-ERK was translocated in an appropriate manner into the nucleus. Accordingly, SK-N-MC cells were treated with either dopamine or SKF R-38393 in a dose- and time-dependent manner, the cells fractionated into cytoplasm and nucleus fractions, and levels of p-ERK1/2 in these fractions were assessed by Western blots. Dopamine and SKF R-38393 (100 µM each) caused a time-dependent increase in p-ERK1/2 levels in both the cytoplasm and the nuclei fractions, reaching maximal levels in 60 min (Fig. 6A). However, the relative increase in p-ERK1/2 in the nuclei was significantly (p < 0.05) below that seen in the cytoplasm at all times. Only 35% of p-ERK1/2 was translocated to the nuclei, whereas 65% of p-ERK1/2 was retained in the cytoplasm after a 60-min treatment with dopamine or SKF R-38393 (Fig. 6A). Similarly, both dopamine and SKF R-38393 caused an increase in p-ERK1/2 in a dose-dependent manner, but there were clearly much higher levels (~65%) of p-ERK1/2 in the cytoplasm compared with the nuclei (Fig. 6B). As a positive control, SK-N-MC cells were treated with forskolin, a cAMP-elevating agent, which caused a dose-dependent increase in p-ERK1/2 levels. In contrast to our findings with dopamine and SKF R-38393, in forskolin-treated cells 72% of p-ERK1/2 was translocated to the nuclei, and only 28% of p-ERK1/2 was retained in the cytoplasm after a 30-min 10 µM forskolin treatment (Fig. 6C).



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 6.
Quantification of subcellular distribution of p-ERK1/2 in dopamine (DA)- or SKF R-38393-treated SK-N-MC cells. A, time course of p-ERK1/2 expression of cytoplasm fraction (upper immunoblot) and nuclear fraction (lower immunoblot) after stimulation with 100 µM dopamine or 100 µM SKF R-38393 in SK-N-MC cells. B, p-ERK1/2 expression of cytoplasm fraction (upper immunoblot) and nuclear fraction (lower immunoblot) after a 1-h treatment with an increased dose of dopamine or SKF R-38393. C, p-ERK1/2 expression of cytoplasm fraction (upper immunoblot) and nuclear fraction (lower immunoblot) after 30-min stimulation with an increased dose of forskolin in SK-N-MC cells. In the bar graph, data are expressed relative to control, untreated cells and represent the percentage average ± S.E. of three independent experiments for each treatment. p < 0.05 (*) and p < 0.01 (**), significantly different from the corresponding cytosolic group.

 
Upon activation, GPCRs are phosphorylated and then coupled to {beta}-arrestin, resulting in endocytosis of the p-GPCR. Once internalized, {beta}-arrestin acts as a scaffolding protein, binding to p-ERK to form a stable complex, leading to the cytosolic retention of the p-GPCR (31–33). We wondered whether stimulation of D1 receptors also results in formation of such heterotrimeric complexes comprising the D1 dopamine receptor, {beta}-arrestin, and p-ERK. Using selective antibodies, we found that these SK-N-MC cells express only the {beta}-arrestin2 protein and not the {beta}-arrestin1 subtype (Fig. 7A). We next treated SK-N-MC cells with 100 µM dopamine or 100 µM SKF R-38393 for different time periods and conducted coimmunoprecipitation studies using antibodies against pan-{beta}-arrestin. p-ERK1/2 was found to be associated with {beta}-arrestin2 within 60 min of treatment with the agonist, followed by a decrease at 120 min of treatment (Fig. 7B). This result is consistent with the time course of dopamine-induced p-ERK1/2 expression (Fig. 2D) and with the time course of dopamine- and SKF R-38393-induced cytosolic retention of p-ERK (Fig. 6A). In all immunopellets, precipitated {beta}-arrestin2 was detected at similar levels (Fig. 7B).




View larger version (72K):
[in this window]
[in a new window]
  		FIG. 7.
Coimmunoprecipitation studies indicated a complex of p-ERK, {beta}-arrestin2, and D1 receptors. A, time course of {beta}-arrestin1 and {beta}-arrestin2 expression of after stimulation with 100 µM dopamine (DA) or 100 µM SKF R-38393 in SK-N-MC cells. WB, Western blot. B, time course of immunoprecipitation (IP) with {beta}-arrestin2 antibody and Western blot with p-ERK1/2 antibody after stimulation with 100 µM dopamine or 100 µM SKF R-38393 in SK-N-MC cells. C, immunoprecipitation with {beta}-arrestin2 antibody and Western blot with p-ERK1/2, D1 receptors, or {beta}-arrestin2 antibody after a 1-h stimulation with 50 and 100 µM dopamine or 50 and 100 µM SKF R-38393 in SK-N-MC cells. D, immunoprecipitation with p-ERK1/2 antibody and Western blot with p-ERK1/2, D1 receptors, or {beta}-arrestin2 antibody after a 1-h stimulation with 50 and 100 µM dopamine or 50 and 100 µM SKF R-38393 in SK-N-MC cells. E, immunoprecipitation with D1 receptor antibody and Western blot with p-ERK1/2 or {beta}-arrestin2 antibody after a 1-h stimulation with 50 and 100 µM dopamine or 50 and 100 µM SKF R-38393 in SK-N-MC cells. In the bar graph, data are expressed relative to control, untreated cells and represent the percentage average ± S.E. of three independent experiments for each treatment. p < 0.05 (*) significantly different from the corresponding dopamine group.

 
We next treated SK-N-MC cells with 50 and 100 µM dopamine or 50 and 100 µM SKF R-38393 for 1 h, and coimmunoprecipitations were conducted on cell lysates with antibodies against pan-{beta}-arrestin (Fig. 7C), p-ERK (Fig. 7D), or the D1 dopamine receptor (Fig. 7E). In pan-{beta}-arrestin immunopellets, both p-ERK and D1 receptors were detected in response to agonists used in a dose-dependent manner to treat the cells; there was an increase of ~120 and 80% with 100 µM dopamine and SKF R-38393, respectively (Fig. 7C). In these immunopellets, {beta}-arrestin2 was detected at similar levels, indicating that there were no differences in the amount of protein present in the pellets (Fig. 7C). In p-ERK-immunoprecipitated extracts, precipitated {beta}-arrestin2, D1 receptor, and p-ERK1/2 were also detected in a dose-dependent manner (Fig. 7D), with an increase in protein levels of ~120% ({beta}-arrestin2), ~80% (D1 receptors), and ~90% (p-ERK1/2) after 100 µM dopamine treatment. An increase of ~80% ({beta}-arrestin2), ~70% (D1 receptors), and ~70% (p-ERK1/2) was similarly seen in 100 µM SKF R-3839-treated cellular extracts. Finally, in coimmunoprecipitations using D1 receptor antibodies, increased levels of p-ERK1/2 and {beta}-arrestin2 (~70% each) were detected in the immunopellets in a dose-dependent manner (Fig. 7E). Together, these results indicate that upon stimulation of D1 receptors with agonist, a stable heterotrimeric protein complex consisting of D1 dopamine receptors, {beta}-arrestin2, and p-ERK1/2 is formed within the SK-N-MC cells.

To verify the participation of {beta}-arrestin2 in the formation of the heterotrimeric complex, we examined the formation of this complex in SK-N-MC cells transfected with a dominant negative mutant of {beta}-arrestin2 ({beta}-arrestin2 V54D), {beta}-arrestin1 dominant negative mutant ({beta}-arrestin1 V53D), or mock (pcDNA3). In mock and {beta}-arrestin1 V53D-transfected cells, the formation of the heterotrimeric complex was increased substantially after 100 µM SKF R-38393 and 100 µM dopamine treatment as shown in coimmunoprecipitation studies (Fig. 8, A–C); whereas, in {beta}-arrestin2 V54D-transfected cells, the formation of the heterotrimeric complex induced by 100 µM SKF R-38393 and 100 µM dopamine was ablated (Fig. 8, A–C). This is in consistent with the finding that stimulation of D1 receptors with agonists forms a stable heterotrimeric protein complex consisting of D1 dopamine receptors, {beta}-arrestin2, and p-ERK1/2, and {beta}-arrestin2 acts as a scaffolding protein.



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 8.
{beta}-Arrestin2 mutant blocks the formation of the D1a receptor-{beta}-arrestin2-p-ERK complex. A, immunoprecipitation with p-ERK1/2 antibody and immunoblotting with {beta}-arrestin2, D1 receptor, and p-ERK1/2 antibody after a 1-h stimulation with 100 µM SKF R-38393 and 100 µM dopamine (DA) in mock transfected (pcDNA3), {beta}-arrestin1 dominant negative mutant ({beta}-arrestin1 V53D)-, or {beta}-arrestin2 dominant negative mutant ({beta}-arrestin2 V54D)-transfected SK-N-MC cells. B, immunoprecipitation with {beta}-arrestin2 antibody and immunoblotting with p-ERK1/2 and D1 receptor antibody after a 1-h stimulation with 100 µM SKF R-38393 and 100 µM dopamine in mock transfected (pcDNA3), {beta}-arrestin1 dominant negative mutant ({beta}-arrestin1 V53D)-, or {beta}-arrestin2 dominant negative mutant ({beta}-arrestin2 V54D)-transfected SK-N-MC cells. C, immunoprecipitation with D1 antibody and immunoblotting with p-ERK1/2 and {beta}-arrestin2 antibody after a 1-h stimulation with 100 µM SKF R-38393 and 100 µM dopamine in mock transfected (pcDNA3), {beta}-arrestin1 dominant negative mutant ({beta}-arrestin1 V53D)-, or {beta}-arrestin2 dominant negative mutant ({beta}-arrestin2 V54D)-transfected SK-N-MC cells.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The MAPKs constitute an important family of signaling proteins (17, 34) that regulate neuronal survival and death, proliferation, differentiation, and plasticity. In particular, ERK is involved in neuronal development, memory formation, survival, and adaption (16, 35–39). Yet, recent studies suggest that activation of the ERK signaling cascade may also induce a cytotoxic neuronal response to stress (40–47), suggesting that ERK signaling may have an alternate function mediating neurotoxic events.

The results presented here provide evidence for the selective participation of ERK in the early events underlying the genesis of striatal cytotoxicity upon stimulation of D1 dopamine receptors. Thus, instead of observing D1 receptor-mediated increases in levels of p-p38 MAPK and p-JNK, the prototypical MAPKs activated in response to oxidative stress, we paradoxically observed a selective increase in p-ERK1/2. The increase in p-ERK1/2 expression was blocked by the D1-selective antagonist, and when SK-N-MC cells were treated with dopamine in the presence of SMBS, the antioxidant failed to affect p-ERK1/2 levels (data not shown). However, inhibition of MEK1/2 by U0126 blocked the SKF R-38393-mediated increase in p-ERK1/2 levels. Moreover, suppression of p-ERK1/2 expression with catalytically defective MEK1 mutant MEK1-K97M also blocked the SKF R-38393- and the dopamine-induced increases in p-ERK1/2 levels and relieved the D1 dopamine receptor-mediated cytotoxicity. Together, these combined data indicate that stimulation of the D1 dopamine receptor leads to p-ERK1/2 activation.

Dopamine, however, appears to activate other MAPKs, in addition to p-ERK1/2. Thus, dopamine also caused a robust increase in p-p38 MAPK, with a modest increase in p-JNK levels, and in the presence of SB203580 or SB600125, nitrite production was significantly attenuated, with partial restoration of cell viability. Moreover, the p-ERK1/2 inhibitors and MEK1-K97M and also caused only partial blockade of nitrite production and cell death. Interestingly, none of these effects was observed with the D1 dopamine receptor-selective agonist SKF R-38393. These results indicate that dopamine-mediated cytotoxicity occurs, at least in part, through the p38 MAPK and JNK, in addition to the ERK, signaling cascades. These findings are in congruence with those obtained using H2O2, which also increased the levels of both p38 MAPK and p-JNK but caused only very modest changes in p-ERK1/2. Inhibition of these kinases, p38 MAPK and p-JNK, also caused a large reduction in nitrite levels and in cell death, after treatment with H2O2. Together, these findings suggest that the oxidative stress pathway induced by both dopamine and H2O2 occurs through the activation of the stress-linked MAPKs, p38 MAPK and JNK. A schematic representation summarizing our findings is presented in Fig. 9, where we show how dopamine can activate the various MAPKs through two distinct pathways: the direct stimulation of the D1 dopamine receptors and through an oxidative pathway, arising from its autoxidation. The D1 dopamine receptors activate p-ERK1/2, whereas the oxidative pathway predominantly activates p-p38 MAPK and p-JNK. However, the possibility that some kinases of the autoxidative pathway of dopamine also activate p-ERK1/2 cannot be entirely eliminated. Indeed, some studies suggest that MEKK1 (MAPK kinase kinase kinase 1), which functions as a stress-activated protein kinase, primarily activating JNK and p38 MAPK, may also induce modest ERK activation (48–50). Thus, our studies do not entirely eliminate the possibility that some coparticipation of the oxidative pathway of dopamine, activating through MEKK1, could also cause modest activation of ERK (Fig. 9).



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 9.
Proposed model of dopamine-induced activation of MAPKs cascade. Dopamine (DA) stimulation of D1 dopamine receptors activates the ERK1/2 signaling pathway via protein kinase A (PKA). Alternatively, the autoxidation of dopamine or H2O2 stimulates p-38 and JNK cascades. After activation, p-ERK1/2, p-JNK, and p-p38 phosphorylate cytoskeletal proteins, cytosolic kinases, or transcription factors, leading to an increase of nitric oxide production and finally cell apoptosis.

 
Activation of the ERK cascade by dopamine receptors is a complex process that may involve multiple mechanisms (51–54). D1 dopamine receptors are known to exert their physiological actions by stimulating cellular adenylyl cyclase via Gs (55). Recent studies show that activation of ERK1/2 occurs via a Gs/adenylyl cyclase/protein kinase A-dependent pathway that causes activation of the small GTPase, Rap1 (56, 57). Our results also indicate the participation of the cAMP/protein kinase A-dependent pathway in these processes, because inhibition of protein kinase A completely blocked D1 receptor-induced ERK activation in SK-N-MC cells.

In resting cells, ERK is kept in the cytoplasm by the microtubule cytoskeleton, which serves as a major docking matrix for up to 35% of cellular ERK1 and ERK2 (58). Other putative cytosol-anchoring proteins of ERK are the MAP kinase phosphatases (MKPs), in particular MKP3 (29, 59). ERK is also retained in the cytosol by its association with MEK1/2 (60). After phosphorylation by MEK1/2, p-ERK1/2 is detached from this cytosolic anchor and rapidly translocated into the nucleus (61), in a process that requires dimerization and phosphate incorporation into the regulatory Thr and Tyr residues of at least one of the ERKs in the dimer (62). Several sites on ERK have been identified to be important in both its nuclear translocation (residues 321–327) and its cytosolic retention (residues 312–320), with the three acidic residues Asp-316, Asp-319, and Glu-320 being especially important (63). Once in the nucleus, p-ERK1/2 can phosphorylate substrates, such as Elk-1 (64), thereby transmitting signals originally received by cell surface receptors to the nucleus.

In our studies, we found that the majority of p-ERK1/2 was retained in the cytoplasm, with only a modest amount translocated into the nucleus. The failure of p-ERK1/2 to translocate into the nucleus, coupled with its retention in the cytoplasm, provides some evidence for a possible mechanism by which ERK activation may trigger a cytotoxic, rather than a mitogenic, response upon activation of the D1 dopamine receptor. In our coimmunoprecipitation studies, we have shown that p-ERK1/2 forms a stable heterotrimeric complex with the D1 dopamine receptor and {beta}-arrestin2. The arrestin proteins enable the internalization and trafficking of certain phosphorylated GPCRs, including the D1 dopamine receptor (65), away from the plasma membrane, terminating receptor-dependent signals by precluding receptor-G protein coupling (66). Blockade of the expression of {beta}-arrestin2 with its dominant negative mutant almost completely prevented the formation of the heterotrimeric complex, while simultaneously blocking the phosphorylation of pERK1/2.

A similar observation has also been made for a limited number of GPCRs. Thus, activation of the protease-activated receptor type 2 (67), vasopressin V2 (68), and the angiotensin AT1a receptor (31) leads to the cytosolic retention of p-ERK, with low transcription activity and lack of a mitogenic response. In all of these studies, the cytosolic pool of p-ERK was shown to form stable complexes with the activated receptors and {beta}-arrestin (69). In other studies with vasopressin V2 receptors, it was shown that the stability of the receptor-{beta}-arrestin complex, and not the specificity of the G protein coupling, was paramount in determining the subcellular distribution of ERK and its retention in the cytosol (31, 70). Interestingly, in human embryonic kidney-293 cells, the rat variant of D1 dopamine receptors was found to form only transient complexes with {beta}-arrestin, whereas both the AT1a and the vasopressin V2 receptors were shown to form stable complexes (32). Yet, our data clearly show that at least in SK-N-MC cells, the D1 dopamine receptor is able to form stable complexes with both {beta}-arrestin2 and p-ERK1/2.

If abnormally retained in the cytoplasm, {beta}-arrestin-bound p-ERK1/2 may phosphorylate multiple plasma membrane, cytoplasmic, and cytoskeletal substrates (34), resulting in altered, and perhaps inappropriate, series of cellular events. The significance of cytosolic retention of p-ERK1/2 is underscored by recent findings in postmortem tissue of neurodegenerative diseases, where neuronal inclusion bodies were found to contain substantially high levels of aggregated p-ERK1/2. Thus, from immunohistochemical analyses, granular precipitates of p-ERK1/2 were seen in the cytoplasm of neurons exhibiting early tau deposition in Alzheimer's disease, in neurons with Pick bodies in Pick's disease, and in neurons in progressive supranuclear palsy and corticobasal degeneration (71). Moreover, p-ERK1/2, but not p-p38 MAPK or p-JNK, was found in Lewy bodies in Parkinson's disease and in dementia with Lewy bodies (72), which were shown to be located primarily in the cytoplasm and not in the nucleus (73). Therefore, elucidation of the precise mechanisms that cause cytosolic retention of p-ERK1/2 is likely to provide important insights into the etiology of multiple neurodegenerative diseases.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grant NS-34914. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Laboratory of Molecular Neurochemistry, Research Bldg., Rm. W222, 3970 Reservoir Rd. NW, Washington, D. C. 20007. Tel.: 202-687-0282; Fax: 202-687-0279; E-mail: sidhua{at}georgetown.edu.

1 The abbreviations used are: SMBS, sodium metabisulfite; ERK1/2, extracellular signal-regulated kinases 1 and 2; GPCR, G protein-coupled receptor; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK1/2; MAPK/ERK kinase 1 and 2; p-, phosphorylated; p38 MAPK, 38-kDa mitogen-activated protein kinase. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Christophe Wersinger for assistance in preparation of the striatal neurons.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ghorayeb, I., Fernagut, P. O., Aubert, I., Bezard, E., Poewe, W., Wenning, G. K., and Tison, F. (2000) Movement Disorders 15, 531–536[CrossRef][Medline] [Order article via Infotrieve]
  2. Stephans, S., and Yamamoto, B. (1996) Neuroscience 72, 593–600[CrossRef][Medline] [Order article via Infotrieve]
  3. LaVoie, M. J., and Hastings, T. G. (1999) J Neurosci. 19, 1484–1491[Abstract/Free Full Text]
  4. Drago, J., Padungchaichot, P., Wong, J. Y., Lawrence, A. J., McManus, J. F., Sumarsono, S. H., Natoli, A. L., Lakso, M., Wreford, N., Westphal, H., Kola, I., and Finkelstein, D. I. (1998) J. Neurosci. 18, 9845–9857[Abstract/Free Full Text]
  5. Hantraye, P. (1998) Nucl. Med. Biol. 25, 721–728[CrossRef][Medline] [Order article via Infotrieve]
  6. Imam, S. Z., el-Yazal, J., Newport, G. D., Itzhak, Y., Cadet, J. L., Slikker, W., Jr., and Ali, S. F. (2001) Ann. N. Y. Acad. Sci. 939, 366–380[Abstract/Free Full Text]
  7. Kitazawa, M., Wagner, J. R., Kirby, M. L., Anantharam, V., and Kanthasamy, A. G. (2002) J. Pharmacol. Exp. Ther. 302, 26–35[Abstract/Free Full Text]
  8. Junn, E., and Mouradian, M. M. (2001) J. Neurochem. 78, 374–383[CrossRef][Medline] [Order article via Infotrieve]
  9. Spencer, J. P., Whiteman, M., Jenner, P., and Halliwell, B. (2002) J. Neurochem. 81, 122–129[CrossRef][Medline] [Order article via Infotrieve]
  10. Stefanova, N., Puschban, Z., Fernagut, P. O., Brouillet, E., Tison, F., Reindl, M., Jellinger, K. A., Poewe, W., and Wenning, G. K. (2003) Acta Neuropathol. 106, 157–166[CrossRef][Medline] [Order article via Infotrieve]
  11. Cools, A. R., Lubbers, L., van Oosten, R. V., and Andringa, G. (2002) Neuropharmacology 42, 237–245[CrossRef][Medline] [Order article via Infotrieve]
  12. Andringa, G., Stoof, J. C., and Cools, A. R. (1999) Psychopharmacology 146, 328–334[CrossRef][Medline] [Order article via Infotrieve]
  13. Wersinger, C., Chen, J., and Sidhu, A. (2004) Mol. Cell. Neurosci. 25, 124–137[CrossRef][Medline] [Order article via Infotrieve]
  14. Chen, J., Wersinger, C., and Sidhu, A. (2003) J. Biol. Chem. 278, 28089–28100[Abstract/Free Full Text]
  15. Sidhu, A., and Fishman, P. H. (1990) Biochem. Biophys. Res. Commun. 166, 574–579[CrossRef][Medline] [Order article via Infotrieve]
  16. Sweatt, J. D. (2001) J. Neurochem. 76, 1–10[CrossRef][Medline] [Order article via Infotrieve]
  17. Johnson, G. L., and Lapadat, R. (2002) Science 298, 1911–1912[Abstract/Free Full Text]
  18. Davis, R. J. (2000) Cell 103, 239–252[CrossRef][Medline] [Order article via Infotrieve]
  19. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843–14846[Free Full Text]
  20. Post, G. R., and Brown, J. H. (1996) FASEB J. 10, 741–749[Abstract]
  21. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726–735[Abstract]
  22. Paul, A., Wilson, S., Belham, C. M., Robinson, C. J., Scott, P. H., Gould, G. W., and Plevin, R. (1997) Cell. Signalling 9, 403–410[CrossRef][Medline] [Order article via Infotrieve]
  23. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  24. Kimura, K., White, B. H., and Sidhu, A. (1995) J. Biol. Chem. 270, 14672–14678[Abstract/Free Full Text]
  25. Sidhu, A., Kimura, K., Uh, M., White, B. H., and Patel, S. (1998) J. Neurochem. 70, 2459–2467[Medline] [Order article via Infotrieve]
  26. Luedtke, R. R., Griffin, S. A., Conroy, S. S., Jin, X., Pinto, A., and Sesack, S. R. (1999) J. Neuroimmunol. 101, 170–187[CrossRef][Medline] [Order article via Infotrieve]
  27. Sidhu, A., Olde, B., Humblot, N., Kimura, K., and Gardner, N. (1999) Neuroscience 91, 537–547[CrossRef][Medline] [Order article via Infotrieve]
  28. Formstecher, E., Ramos, J. W., Fauquet, M., Calderwood, D. A., Hsieh, J. C., Canton, B., Nguyen, X. T., Barnier, J. V., Camonis, J., Ginsberg, M. H., and Chneiweiss, H. (2001) Dev. Cell 1, 239–250[CrossRef][Medline] [Order article via Infotrieve]
  29. Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouyssegur, J. (1999) EMBO J. 18, 664–674[CrossRef][Medline] [Order article via Infotrieve]
  30. Hochholdinger, F., Baier, G., Nogalo, A., Bauer, B., Grunicke, H. H., and Uberall, F. (1999) Mol. Cell. Biol. 19, 8052–8065[Abstract/Free Full Text]
  31. Tohgo, A., Choy, E. W., Gesty-Palmer, D., Pierce, K. L., Laporte, S., Oakley, R. H., Caron, M. G., Lefkowitz, R. J., and Luttrell, L. M. (2003) J. Biol. Chem. 278, 6258–6267[Abstract/Free Full Text]
  32. Oakley, R. H., Laporte, S. A., Holt, J. A., Caron, M. G., and Barak, L. S. (2000) J. Biol. Chem. 275, 17201–17210[Abstract/Free Full Text]
  33. Tohgo, A., Pierce, K. L., Choy, E. W., Lefkowitz, R. J., and Luttrell, L. M. (2002) J. Biol. Chem. 277, 9429–9436[Abstract/Free Full Text]
  34. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman, K., and Cobb, M. H. (2001) Endocr. Rev. 22, 153–183[Abstract/Free Full Text]
  35. Segal, R. A., and Greenberg, M. E. (1996) Annu. Rev. Neurosci. 19, 463–489[Medline] [Order article via Infotrieve]
  36. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326–1331[Abstract/Free Full Text]
  37. Atkins, C. M., Selcher, J. C., Petraitis, J. J., Trzaskos, J. M., and Sweatt, J. D. (1998) Nat. Neurosci. 1, 602–609[CrossRef][Medline] [Order article via Infotrieve]
  38. English, J. D., and Sweatt, J. D. (1996) J. Biol. Chem. 271, 24329–24332[Abstract/Free Full Text]
  39. Davis, R. J. (1993) J. Biol. Chem. 268, 14553–14556[Free Full Text]
  40. Alessandrini, A., Namura, S., Moskowitz, M. A., and Bonventre, J. V. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12866–12869[Abstract/